Kane Michael, Donofrio Lisa, Ascher Benjamin, Hexsel Doris, Monheit Gary, Rzany Berthold, Weiss Robert
J Drugs Dermatol. 2010 Jan;9(1 Suppl):s7-22; quiz s23-5.
Injection of botulinum toxin type A (BoNTA) is the most common nonsurgical aesthetic procedure undertaken in the United States (U.S.). A new formulation of BoNTA (abobotulinumtoxinA, Dysport™) has recently been approved in the U.S. for the treatment of glabellar lines. This product has been used for facial aesthetics in other parts of the world for more than 15 years, whereas in the U.S. a different formulation (onabotulinumtoxinA, Botox® Cosmetic) has been used for many years. The various formulations of neurotoxins are unique and are not interchangeable nor are doses convertible from one product to another, so it is important that recommendations be developed to assist U.S. clinicians in understanding the differences between the two available formulations of BoNTA, which should ensure successful outcomes with these products. A group of worldwide experts on the aesthetic use of BoNTA convened in February 2009 in New York, NY, to review the use of BoNTA and to develop consensus recommendations for the use of the new formulation, since such guidelines previously had only been published in German. This publication summarizes key discussions from the meeting as well as recommendations and suggestions regarding the use of abobotulinumtoxinA in the areas of the face most commonly treated with BoNTA.
注射A型肉毒杆菌毒素（BoNTA）是美国最常见的非手术美容方法。一种新型BoNTA（阿柏西普肉毒杆菌毒素A，商品名Dysport™）最近在美国被批准用于治疗眉间纹。该产品在世界其他地区用于面部美容已有15年多，而在美国，另一种制剂（保妥适肉毒杆菌毒素A，商品名Botox® Cosmetic）已使用多年。各种神经毒素制剂都有其独特之处，不可互换，剂量也不能从一种产品换算到另一种产品，因此制定相关建议以帮助美国临床医生了解两种可用BoNTA制剂之间的差异很重要，这应能确保使用这些产品取得成功效果。2009年2月，一群全球范围内的BoNTA美容应用专家在纽约召开会议，审查BoNTA的使用情况，并就新制剂的使用制定共识性建议，因为此前此类指南仅以德语发表。本出版物总结了会议的关键讨论内容以及关于在BoNTA最常治疗的面部区域使用阿柏西普肉毒杆菌毒素A的建议和意见。
